Schwarz, Caroline
Chromy, David
Bauer, David
Duong, Nikki
Schmidbauer, Victor Ulrich
Schwarz, Michael
Mandorfer, Mattias
Rieger, Armin
Trauner, Michael
Gschwantler, Michael
Reiberger, Thomas http://orcid.org/0000-0002-4590-3583
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 19 September 2022
Accepted: 19 November 2022
First Online: 28 December 2022
Declarations
:
: C. Schwarz received travel support from Gilead, Abbvie, and Gebro; speakers honoraria from Abbvie and Gilead; and served as a consultant for Gilead. D. Chromy served as a speaker and/or consultant and/or advisory board member for AbbVie, Gilead, and MSD, and received travel support from AbbVie, MSD, ViiV Healthcare, and Gilead. D. Bauer received travel support from Gilead and Abbvie and speaker fees from Abbvie. M. Schwarz received speakers honoraria from BMS and travel support from BMS, MSD, Abbvie and Gilead. M. Mandorfer served as a speaker and/or consultant and/or advisory board member for AbbVie, Bristol-Myers Squibb, Collective Acumen, Gilead, and W. L. Gore & Associates and received travel support from AbbVie, Bristol-Myers Squibb, and Gilead. M. Trauner received grant support from Albireo, Alnylam, Cymabay, Falk, Gilead, Intercept, MSD, Takeda and Ultragenyx, honoraria for consulting from Albireo, Boehringer Ingelheim, BiomX, Falk, Genfit, Gilead, Intercept, MSD, Novartis, Phenex, Regulus and Shire, speaker fees from Bristol-Myers Squibb, Falk, Gilead, Intercept and MSD, as well as travel support from AbbVie, Falk, Gilead and Intercept and is the co-inventor of patents on the medical use of 24-norursodesoxycholic acid. M. Gschwantler received grant support from Abbvie, Gilead and MSD; speakers honoraria from Abbvie, Gilead, Intercept, Janssen, BMS, Roche, Norgine, AstraZeneca, Falk, Shionogi, and MSD; consulting/advisory board fees from Abbvie, Gilead, Intercept, Janssen, BMS, Roche, Alnylam, Norgine, AstraZeneca, Falk, Shionogi and MSD; and travel support from Abbvie and Gilead. T. Reiberger received grant support from Abbvie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speakers honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead and Roche. N. Duong, V.U. Schmidbauer and A. Rieger declare that they have no competing interests.
: The study was approved by the ethics committee of the Medical University of Vienna on 7 July 2017 (EC Number: 1527/2017). The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki (6th revision, 2008) as reflected in a priori approval by the institution’s human research committee. Due to the retrospective character of the study, the ethics committee waived the need for written informed consent.